Cleveland Biolabs Inc. (NASDAQ: CBLI) stock declined by 8.87% in the current market trading session. Depending on a patented platform designed to reset the body’s immune system and reestablish homeostasis, Cytocom is a clinical-stage pharmaceutical business researching new therapeutics for autoimmune, anemia, evolving viruses, and malignancies.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s happening in CBLI stock?
The La Jolla Institute for Immunology (LJI), a not-for-profit academic organization and a world leader in immunology research, has announced a joint venture to support research and laboratory facilities. The study will help the development of possible novel immune-modulating drugs targeting toll-like receptors for cancer therapy, infectious, autoimmune, and chronic inflammatory disorders, according to the contract. Cytocom’s unique pharmaceutical research and development platform technology will be used in the study.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
The La Jolla Institute may choose up to four laboratories to engage in research under the conditions of the research deal. These laboratories will receive research funding from Cytocom for studies of common interest or research projects funded by Cytocom that investigate immune regulation and therapeutic effect on target toll-like receptors. Toll-like receptors are important components of the immune system because they link the innate and adaptive immune compartments, making them important in both combating illness and restoring immunological homeostasis.
Cytocom will also supply samples and supplies to researchers at the La Jolla Institute. In exchange, Cytocom will have first choice to negotiate a license for new discoveries made by the La Jolla Institute as a result of Cytocom-funded research projects of common interest, however, Cytocom will retain ownership of any new discoveries made by the La Jolla Institute as a result of Cytocom-commissioned “work for hire” research projects.
Michael K. Handley, President and CEO of Cytocom stated,
A partnership with a prestigious academic institution like the La Jolla Institute is a significant step forward for Cytocom and their aim to develop best-in-class immune-modulating treatments that restore immunological homeostasis. They now have a strong pipeline of immune-modulating therapies for neutropenia and anemia, emerging infections, cancer, and autoimmune disorders, due to the combination of Cleveland BioLabs and Cytocom. With their AIMS technology and the help of the La Jolla Institute, they will investigate the processes that they anticipate will fuel next-generation therapeutic innovation and provide hope to patients and their families dealing with significant medical illnesses.
